14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
TWST vs MTLS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Materialise NV (MTLS) is the stronger overall head-to-head candidate over Twist Bioscience Corporation (TWST) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TWST carries a Unified Composite Score of 58.9/100 (HOLD) at $112.00 (N/M Forward P/E, -28.8% operating margin), whereas MTLS carries 53.5/100 (HOLD) at $6.28 (N/M Forward P/E, 3.4% operating margin).
Composite vs. Pillar Nuance: While TWST currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. MTLS 53.5/100 HOLD), MTLS captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (3.4% vs. -28.8% operating margin) and revenue trajectory (+2.1% vs. +27.9% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TWST vs MTLS. Trailing 12-month operating profitability (TWST -28.8% vs MTLS 3.4%) and valuation multiples (TWST N/M vs MTLS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Software - Application value chain with $369.9M market capitalization and 3.4% operating margin.
OpEx & R&D Reinvestment54.0% of Rev ($327M)
90D Engineering Disclosures0 Published
Investor FAQ TWST vs MTLS Key Questions & Quantitative Answers
As of Nov 17, 2026, Materialise NV (MTLS) is the stronger overall head-to-head candidate over Twist Bioscience Corporation (TWST) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). TWST carries a Unified Composite Score of 58.9/100 (HOLD) at $112.00 (N/M Forward P/E, -28.8% operating margin), whereas MTLS carries 53.5/100 (HOLD) at $6.28 (N/M Forward P/E, 3.4% operating margin). Composite vs. Pillar Nuance: While TWST currently prints a higher short-term Unified Composite Score (58.9/100 HOLD vs. MTLS 53.5/100 HOLD), MTLS captures the overall institutional head-to-head verdict (5–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (3.4% vs. -28.8% operating margin) and revenue trajectory (+2.1% vs. +27.9% YoY).
TWST leads the Growth & Scale pillar: TWST posts +27.9% YoY revenue growth and +0.0% YoY earnings growth on $459M TTM revenue (52.4% gross margin, -28.8% operating margin), compared with MTLS at +2.1% YoY revenue growth and -33.3% YoY earnings growth on $605M TTM revenue (57.4% gross margin, 3.4% operating margin). On trailing 12-month operating scale, TWST generates $459M in USD-normalized revenue versus $605M for MTLS. In operating R&D and SG&A reinvestment, TWST deploys 81.2% of Rev ($373M) (0 90-day corporate R&D disclosures) versus 54.0% of Rev ($327M) (0 disclosures) for MTLS.
MTLS screens cheaper on headline valuation multiples. TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.1x EV/Revenue (-23.4% EBITDA margin), whereas MTLS trades at N/M Forward P/E, 25.0x Trailing P/E, 1.26x PEG, and 0.6x EV/Revenue (9.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TWST (-19.1% ROE) versus MTLS (5.0% ROE) capital efficiency.
In options market volatility and institutional positioning, TWST carries 100.1% implied volatility (19th %ile, Compressed (<25th %ile)), a 1.31x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.07β · 125% Vol realized risk). By comparison, MTLS carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.10β · 88% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.